Company Encyclopedia
View More
name
Keqian Biology
688526.SH
Wuhan Keqian Biology Co.,Ltd focuses on the research and development, production, sales, and animal epidemic prevention technical services of veterinary biological products in China. The company offers vaccines for pigs, poultry, and pets, as well as diagnostic reagents. Wuhan Keqian Biology Co.,Ltd was founded in 2001 and is based in Wuhan, China.
3.165 T
688526.SHMarket value -Rank by Market Cap -/-

Financial Score

09/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking44/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE11.45%B
    • Profit Margin45.31%A
    • Gross Margin67.37%A
  • Growth ScoreB
    • Revenue YoY12.43%B
    • Net Profit YoY53.64%B
    • Total Assets YoY7.24%B
    • Net Assets YoY8.14%B
  • Cash ScoreC
    • Cash Flow Margin220.72%C
    • OCF YoY12.43%B
  • Operating ScoreD
    • Turnover0.22D
  • Debt ScoreA
    • Gearing Ratio12.21%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Keqian Biology: Net profit in the third quarter was 118 million yuan, a year-on-year increase of 9.17%

    Keqian Biology announced that the revenue for the third quarter was 251 million yuan, a year-on-year decrease of 5.44%; the net profit was 118 million yuan, a year-on-year increase of 9.17%. The revenue for the first three quarters was 738 million yuan, a year-on-year increase of 10.87%; the net profit was 338 million yuan, a year-on-year increase of 29.62%

    Zhitong·
    SH
    688526
    -1.02%
    Zhitong·
    SH
    688526
    -1.02%

    Keqian Biology's actual controller renews the concerted action agreement to consolidate the company's control

    Keqian Biology's actual controller renewed the concerted action agreement on September 17, consolidating the company's control. The new agreement is valid until September 21, 2026, clarifying the purpose of concerted action and the decision-making mechanism. After the renewal, the actual control remains unchanged, which helps stabilize the control of the company, maintain strategic and operational coherence, promote healthy and sustainable development, and protect the interests of small and medium investors

    Zhitong·
    SH
    688526
    -1.02%
    Zhitong·
    SH
    688526
    -1.02%

    Keqian Biology released its performance for the first half of the year, with a net profit attributable to the parent company of 220 million yuan, an increase of 44.09%

    Keqian Biology released its 2025 semi-annual report, with operating revenue of 487 million yuan, a year-on-year increase of 21.67%; net profit attributable to the parent company was 220 million yuan, a year-on-year increase of 44.09%. The net profit after deducting non-recurring gains and losses was 190 million yuan, a year-on-year increase of 43.12%. Basic earnings per share were 0.47 yuan, benefiting from improved market conditions and increased sales

    Zhitong·
    SH
    688526
    -1.02%
    Zhitong·
    SH
    688526
    -1.02%

    Keqian Biology: Plans to pay 4.9 million yuan to sign a cooperative research and development agreement with Huazhong Agricultural University

    Keqian Biology announced that the company has obtained cooperation and research and development for four projects through competitive negotiations with Huazhong Agricultural University, and plans to sign a joint development agreement with Huazhong Agricultural University, requiring a total payment of 4.9 million yuan. The technological achievements and intellectual property generated from the cooperative research and development projects will be jointly owned by the company and Huazhong Agricultural University. This related party transaction constitutes a non-significant asset reorganization, has been approved by the board of directors and the supervisory board, and does not need to be submitted for shareholder meeting approval

    Zhitong·
    SH
    688526
    -1.02%
    Zhitong·
    SH
    688526
    -1.02%

    Keqian Biology Buys Rights for Pig, Dog Vaccines for 3.4 Million Yuan

    Wuhan Keqian Biology agreed to co-own the rights for two vaccines for pigs and dogs with the Huazhong Agricultural University for 3.4 million yuan, according to a Shanghai bourse disclosure on Thursday. The Chinese veterinary biological products producer will pay 1.4 million yuan for the invention patent of the porcine deltacoronavirus vaccine, which is valid until March 20, 2042. Keqian Bio will also pay 2 million yuan to co-develop and share domestic production rights to develop the vaccine against Babesia gibsoni, a parasite that infects dogs.

    Trading View·
    SH
    688526
    -1.02%
    Trading View·
    SH
    688526
    -1.02%
    © 2025 Longbridge｜Disclaimer